Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease

Table 5 CSF P-tau, VILIP-1, and YKL-40 across clinical diagnoses and Aβ pathology

Different groups	P-tau	VILIP-1	YKL-40	Difference P-tau vs VILIP-1	Difference P-tau vs YKL-40	Difference VILIP-1 vs YKL-40
Associations between neurodegeneration biomarkers and Aβ pathology within diagnostic group
CN Aβ⁻ vs CN Aβ⁺	0.500 (0.033)	0.372 (0.168)	0.582 (0.144)	0.128 (0.713)	−0.083 (0.855)	−0.211 (0.657)
sMCI Aβ⁻ vs sMCI Aβ⁺	0.854 (0.014)	− 0.014 (0.970)	0.210 (0.634)	0.869 (0.092)	0.645 (0.246)	−0.224 (0.699)
pMCI Aβ⁻ vs pMCI Aβ⁺	1.130 (0.002)	0.619 (0.017)	0.466(0.291)	0.516 (0.371)	0.669 (0.243)	0.153 (0.809)
Associations between neurodegeneration biomarkers and combinations of clinical diagnosis and Aβ pathology
CN Aβ⁻ vs CN Aβ⁺	0.500 (0.033)	0.372 (0.168)	0.582(0.144)	0.128 (0.713)	−0.083 (0.855)	−0.211 (0.657)
CN Aβ⁻ vs sMCI Aβ⁺	0.716 (0.003)	0.274 (0.236)	0.055 (0.875)	0.442 (0.181)	0.661 (0.124)	0.219(0.603)
CN Aβ⁻ vs pMCI Aβ⁺	1.120 (< 0.001)	0.941 (< 0.001)	0.344 (0.191)	0.176 (0.590)	0.773 (0.032)	0.597 (0.107)
CN Aβ⁻ vs AD Aβ⁺	1.100 (< 0.001)	0.789 (0.007)	0.668 (0.038)	0.313 (0.378)	0.435 (0.262)	0.121 (0.773)
CN Aβ⁻ vs sMCI Aβ⁻	−0.234 (0.261)	0.244 (0.439)	−0.198 (0.595)	− 0.477 (0.214)	−0.036 (0.934)	0.441 (0.370)
CN Aβ⁻ vs pMCI Aβ⁻	−0.130 (0.560)	− 0.018 (0.959)	−0.264 (0.583)	− 0.112 (0.785)	0.134 (0.800)	0.246 (0.678)

In different combinations of clinical diagnosis and Aβ pathology, data are are estimates from linear mixed-effects models evaluating effects of Aβ within diagnostic groups (top 3 rows), and differences between Aβ⁻ CN and other combinations of diagnosis and Aβ pathology (bottom 6 rows). Results are β-coefficient (P-value). Bold values indicate significant associations
Abbreviations: VILIP-1 Visinin-like protein-1, YKL-40 Chitinase-3-like protein 1, CN cognitively normal, sMCI stable mild cognitive impairment, pMCI progressive mild cognitive impairment, AD Alzheimer’s disease

ISSN: 2047-9158